Overview

Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

Status:
Active, not recruiting

Trial end date:
2024-08-01

Target enrollment:

Participant gender:

Summary

A multicenter trial evaluating the combination of nivolumab and the antagonistic CSF-1R monoclonal antibody cabiralizumab (BMS-986227) in patients with relapsed/refractory peripheral T cell lymphoma

Phase:

Phase 2

Details

Lead Sponsor:

Big Ten Cancer Research Consortium
Ryan Wilcox

Collaborators:

Bristol-Myers Squibb
University of Michigan Rogel Cancer Center

Treatments:

Antibodies
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Immunoglobulin G
Immunoglobulins
Nivolumab